did-you-know? rent-now

Amazon no longer offers textbook rentals. We do!

did-you-know? rent-now

Amazon no longer offers textbook rentals. We do!

We're the #1 textbook rental company. Let us show you why.

9783540411239

Acute Leukemias VIII: Prognostic Factors and Treatment Strategies

by
  • ISBN13:

    9783540411239

  • ISBN10:

    3540411232

  • Edition: 1st
  • Format: Hardcover
  • Copyright: 2001-04-01
  • Publisher: SPRINGER

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.

Purchase Benefits

  • Free Shipping Icon Free Shipping On Orders Over $35!
    Your order must be $35 or more to qualify for free economy shipping. Bulk sales, PO's, Marketplace items, eBooks and apparel do not qualify for this offer.
  • eCampus.com Logo Get Rewarded for Ordering Your Textbooks! Enroll Now
List Price: $299.00 Save up to $280.44
  • Rent Book $198.84
    Add to Cart Free Shipping Icon Free Shipping

    TERM
    PRICE
    DUE
    USUALLY SHIPS IN 7-10 BUSINESS DAYS
    *This item is part of an exclusive publisher rental program and requires an additional convenience fee. This fee will be reflected in the shopping cart.

Supplemental Materials

What is included with this book?

Summary

Univ. of Munster, Germany. Presents the rapid progress in the medical understanding of leukemia and the identification of novel therapeutic approaches for the disease. Coverage includes first-hand reports from leading study groups and the latest updates on multicenter trials of new therapies. DNLM: Leukemia--Therapy.

Table of Contents

Leukemia Cell Biology, Monitoring, and Prognosis
Mechanisms of Chromosomal Translocation Breakpoints
3(8)
P.D. Aplan
M. Stanulla
Hematologic Malignancies Following Organ Transplantation
11(4)
H.E. Wilczek
C. Brattstrom
Molecular Cytogenetic Characterization of a Critical Region in Bands 7q35-q36 Commonly Deleted in Malignant Myeloid Disorders
15(5)
K. Dohner
U. Hehmann
J. Brown
C. Hetzel
J. Stewart
G. Lowther
C. Scholl
S. Frohling
A. Cuneo
L.C. Tsui
P. Lichter
S.W. Scherer
H. Dohner
Molecular Characterization of the Translocation (10;11) (p13;q14): MLL and CALM are Fused to AF10 in Morphologically Different Subsets of Acute Leukemia
20(7)
M.H. Dreyling
K. Schrader
V. Muschinsky
C. Fonatsch
B. Schlegelberger
D. Haase
C. Schoch
W.-D. Ludwig
W. Hiddemann
S.K. Bohlander
MLL-Duplications are Rare and Associated with Poor Prognosis in Acute Myeloid Leukemia
27(7)
S. Schnittger
U. Kinkelin
C. Schoch
D. Haase
T. Haferlach
T. Buchner
B. Wormann
W. Hiddemann
F. Griesinger
Real-Time RT-PCR for the Detection and Quantification of AML1/MTG8 Fusion Transcripts in Patients with t(8;21) Positive AML
34(6)
J. Krauter
M.P. Wattjes
S. Nagel
O. Heidenreich
U. Krug
S. Kafert
D. Bunjes
L. Bergmann
A. Ganser
G. Heil
Combined Cytogenetic, FISH and RT-PCR Technique in Detection of t(15;17) and Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia
40(4)
Yu. V. Olshanskaya
I.A. Demidova
N.G. Tiurina
A.I. Udovitchenko
L.A. Vodinskaya
A.B. Sudarikov
R.G. Kuliev
E.N. Parovitchanikova
E.V. Domratcheva
V.G. Savchenko
RT-PCR in Diagnostics and Monitoring of Acute Myeloid
44(5)
S. Schnittger
C. Schoch
F. Griesinger
T. Buchner
H. Loffler
T. Haferlach
W. Hiddemann
Chromosome Aberrations in Primary and Secondary Acute Myeloblastic Leukemia
49(5)
O. Haus
M. Czarnecka
S. Kotlarek-Haus
K. Kuliczkowski
E. Duszenko
I. Makowska
Are there Two Main Categories of de Novo Acute Myeloid Leukemias with a Normal Karyotype?
54(7)
P. Lemez
J. Galikova
T. Haas
Asynchronous Expression of AC133 on CD34-Negative Leukemic Blast Cells in Childhood B-Cell Precursor ALL
61(3)
G. Baersch
M. Baumann
J. Ritter
H. Jurgens
J. Vormoor
Expression of AC133 in Childhood Acute Leukemia
64(8)
U. Ebener
S. Wehner
A. Brinkmann
E. Niegemann
B. Kornhuber
CD10 Expression in T-Lineage Adult Acute Lymphoblastic Leukemia
72(6)
X. Thomas
Ch. Charrin
J.-P. Magaud
D. Fiere
Acute Lymphoblastic Leukemia in Childhood with an Unusual Immunophenotype (CD7+/CD56+/CD33+)
78(7)
U. Ebener
S. Wehner
E. Niegemann
B. Kornhuber
Expression of IGFBP-rP2/CTGF is Specific for Malignant Lymphoblasts of Children with Acute Lymphoblastic Leucemia (ALL)
85(4)
P. Vorwerk
J. Elsner
K. Mohnike
Y. Oh
R.G. Rosenfeld
U. Mittler
NM23-H1 Protein Expression as a New Prognostic Factor in Acute Lymphoblastic Leukemia
89(7)
B. Hochsmann
E. Muller
G. Heil
N. Frickhofen
L. Bergmann
Monitoring of Wilms' Tumor Gene Transcription in Leukemia Patients
96(4)
E. Niegemann
S. Wehner
D. Schwabe
U. Ebener
Effect of Mutationally Activated Ras on the Ras to MAP Kinase Signaling Pathway and Growth Inhibition of Myeloid Leukemia Cells by Inhibitors of the MAP Kinase Cascade
100(9)
Ch. W.M. Reuter
M.A. Morgan
L. Bergmann
C-Jun is a JNK-Independent Coactivator of the PU.1 Transcription Factor
109(3)
G. Behre
A.J. Whitmarsh
M.P. Coghlan
T. Hoang
C.L. Carpenter
D.-E. Zhang
R.J. Davis
W. Hiddemann
D.G. Tenen
CD7+ and CD56+ Acute Myelogeneous Leukemia is a Distinct Biologic and Clinical Disease Entity
112(8)
C. Kahl
A. Florschutz
S. Leuner
K. Jentsch-Ullrich
A. Franke
C.R. Bartram
H.-G. Hoffkes
The Role of Apoptosis in the Course of Acute Leukemia in Children
120(4)
A. Chybicka
D. Turkiewicz
B. Rybka
R. Ryczan
J. Boguslawska-Jaworska
Evaluation of Spontaneous and Therapeutically Induced Apoptosis in Childhood Leukemias
124(4)
I. Malinowska
M. Wasik
A. Stelmaszczyk
E. Gorska
M. Steczowicz
R. Rokicka-Milewska
Involvement of BCL-2 and Bax in the IL-7-Induced Inhibition of Spontaneous Apoptosis in Childhood T-ALL
128(8)
V. Ruppert
C. Wuchter
B. Dorken
W.-D. Ludwig
L. Karawajew
Analysis of the Apoptotic Signal Transduction Cascade and New Differentially Expressed Genes in Drug Resistant and Sensitive Hematopoetic Cell Lines
136(10)
G. Beyer-Sehlmeyer
M. Kneba
W. Hiddemann
B. Wormann
J. Bertram
Transforming Activity of Flt3 in 32D Cells
146(6)
M. Mizuki
W. Gruning
R. Schmidt
S. Serve
R. Fenski
K. Kratz-Albers
T. Buchner
J. Kienast
W.E. Berdel
H. Serve
Evidence of Angiogenesis in Acute Myeloid Leukemia
152(8)
T. Padro
S. Ruiz
R.H. Burger
M. Steins
R. Bieker
J. Kienast
T. Buchner
W. Bocker
W.E. Berdel
R.M. Mesters
Significance of AC133 and CD34 Expression on Acute Myeloid Leukemia Cells
160(6)
P.A. Horn
H. Tesch
P. Staib
C. Schoch
D. Kube
V. Diehl
D. Voliotis
Heterogeneity in the Stem Cell Compartment of Newly Diagnosed Acute Myeloid Leukemia Analyzed by 4-Colour Immunofluorescence
166(3)
O. Albrecht
M. Zuhlsdorf
G. Baersch
J. Vormoor
T. Buchner
Validation of the IPSS and Other Scoring Systems in Patients with Primary MDS
169(3)
C. Aul
U. Germing
C. Strupp
A. Giagounidis
G. Meckenstock
Although Patients with AML and Complex Aberrant Karyotype Can be Subdivided Into Different Subtypes by Cytogenetics, Prognosis is Equally Poor
172(7)
C. Schoch
M. Klaus
S. Bursch
T. Buchner
H. Loffler
T. Haferlach
W. Hiddemann
Recent Antileukemic Strategies
Pharmacokinetics of Idarubicin: Intracellular Events and Extracellular Concentrations
179(5)
F. Gieseler
M. Clark
K. Stiebeling
M. Puschmann
S. Valsamas
Oral Idarubicin in Maintenance Therapy of Acute Myeloid Leukemia
184(7)
M. Musso
F. Porretto
A. Crescimanno
F. Bondi
V. Polizzi
R. Scalone
M. Tolomeo
G. Mariani
Phase I Study of Liposomal Daunorubicin (DaunoXome) in Relapsed and Refractory Acute Myeloid Leukemia
191(5)
C. Lerchenmuller
W.E. Berdel
T. Buchner
Multi Centre Study of a Combination of Fludarabine Phosphate, Cytosine Arabinoside and Granulocyte Colony Stimulating Factor (FLAG) in Relapsed and Refractory Acute Myeloid Leukaemia and in De Novo RAEB-t
196(5)
S. Proctor
Modulation of AraC by Fludarabine: Results of Salvage Therapy by AMLCG
201(9)
W. Kern
A. Matylis
T. Gruneisen
C. Huber
A. Grote-Metke
B. Wormann
T. Buchner
J. Ohnesorge
W.-D. Ludwig
W. Hiddemann
Colony Stimulating Factors in Myelodysplastic Syndromes
210(8)
G. Verhoef
Modulation of Ara-C Toxification by Fludarabine and Hydroxyurea in Leukemia Blasts
218(5)
M. Ahlmann
K. Lumkemann
C. Lanvers
A. Freund
C. Rossig
J. Boos
Drug Monitoring of Doxorubicin in Children
223(4)
S. Flege
G. Hempel
P. Schulze-Westhoff
N. Laubrock
J. Boos
Pharmacokinetics of Daunorubicin Entrapped in Liposomes or Erythrocytes - Phase II Study in Refractory Acute Leukemias
227(4)
V.G. Savchenko
E.N. Parovchnikova
A:A. Skorokhod
T.Z. Garmaeva
V.G. Isaev
A.V. Pivnik
V.M. Vetvitsky
F.I. Attaulakhanov
Drug Monitoring During Maintenance Therapy in Children with ALL
231(5)
T. Wessel
G. Hempel
J. Boos
Modulation of Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia; Preliminary Results
236(8)
E.G. Haarmann
G.J.L. Kaspers
R. Pieters
M.M.A. Rottier
A.J.P. Veerman
In-Vitro Cellular Drug Resistance in Acute Non-Lymphoblastic Leukemia: Comparisons Between Adults and Children
244(7)
T.G.K. De Haas
Ch. M. Zwaan
M.J. Wondergem
R. Pieters
G.J.L. Kaspers
A.H. Loonen
M.M.A. Rottier
R. Wunsche
U. Creutzig
S. Bartl
K. Hahlen
H.J. Broxterman
G.J. Ossenkoppeg
A.J.P. Veerman
Prognostic Relevance of In-Vitro Drug Sensitivity Testing in Adult AML
251(6)
R. Staib
T. Schinkothe
S. Wiedenmann
T. Dimski
C. Schoch
D. Voliotis
P.A. Horn
H. Tesch
B. Lathan
V. Diehl
Antileukemic Effects of Buthionine Sulfoximine (BSO) (NSC 326231) In Vivo: A Pilot Study in Acute Myeloblastic Leukemia
257(8)
J.E. Curtis
D.W. Hedley
M.D. Minden
M.A. Moore
E.A. McCulloch
Dendritic Cells Generated out of Blasts from Patients with Acute Leukemia
265(8)
T. Kohler
R. Plettig
W. Wetzstein
G. Ehninger
M. Bornhauser
Generation of Leukemia- Derived Dendritic Cells from Patients with AML
273(9)
A. Berer
F. Keil
O. Haas
K. Lechner
K. Geissler
L. Ohler
Dendritic Cells from AML Patients in Complete Remission are Capable to Present Antigen to Autologous T Lymphocytes
282(5)
D.K. Schui
L. Singh
A. Krapohl
B. Schneider
D. Hoelzer
E. Weidmann
Antibody Response to Neuraminidase of the Influenza Virus in Children with Acute Lymphoblastic Leukaemia Vaccinated against Influenza after Chemotherapy
287(4)
R. Rokicka-Milewska
L.B. Brydak
M. Machala
T. Jackowska
Expansion and Fibronectin-Enhanced Retroviral Transduction of Primary Human T Lymphocytes for Adoptive Immunotherapy
291(18)
M. Stockschlader
S. Exner
O. Schmah
J. Finke
Recent Strategies Against Opportunistic Infections
Early Empiric Antifungal Treatment of Infections in Neutropenic Patients with Hematological Malignancies Comparing Fluconazole with Amphotericin B and 5-Flucytosine
309(6)
G. Silling
W. Fegeler
N. Roos
M. Essink
T. Buchner
The Role of Newer Quinolones in the Management of Infections in Patients with Hematologic Malignancies
315(6)
K.V.I. Rolston
Fungal Infections in Paediatric Haematology
321(3)
I.M. Hann
Empirical Antimicrobial Therapy of FUO and Proved Infections in Neutropenic Patients
324(6)
M. Wilhelm
W. Hiddemann
G. Maschmeyer
H. Link
D. Buchheidt
B. Glass
O. Cornely
M. Helmerking
D. Adam
Multivariate Analysis of Prognostic Factors in Patients with Refractory and Relapsed Acute Myeloid Leukemia Undergoing Sequential High-Dose Cytosine Arabinoside and Mitoxantrone (S-HAM) Salvage Therapy: Significance of Cytogenetic Abnormalities
330(9)
W. Kern
C. Schoch
T. Haferlach
J. Braess
M. Unterhalt
B. Wormann
T. Buchner
W. Hiddemann
Incidence of Central Venous Catheter (CVC)-Infections in Patients with Acute Leukemia
339(5)
M. Karthaus
T. Doellmann
T. Klimasch
J. Krauter
G. Heil
A. Ganser
Do we Need a Triple Antibiotic Therapy?
344(2)
G. Heussel
C.P. Heussel
A. Ullmann
D. Domkin
M. Klousche
G. Derigs
K. Kolbe
Study of G-CSF Influences on CD10 and CD64 Distribution on Neutrophils in Leukemic Patients
346(7)
S. Wehner
S. Weber
E. Niegemann
U. Ebener
RHuGM-CSF (Molgramostim) in the Treatment of Children and Adolescents with Acute Myeloid Leukemia
353(6)
S. Donska
J. Bazaluk
O. Ryzhak
All in Children
CCG Experience with the Augmented BFM Regimen
359(5)
J.B. Nachmann
Pharmacodynamics in Childhood Acute Lymphoblastic Leukemia
364(6)
C.-H. Pui
M.V. Relling
J.T. Sandlund
D. Campana
W.E. Evans
The Late Effects of Prophylactic CNS Treatment
370(11)
Th. Langer
P. Krappmann
S. Kochendorfer
DM. Kusch
U. Gobel
W. Huk
P. Martus
J.D. Beck
The Use of PEG-Asparaginase in Leukemic Children with Prior Hypersensitivity to Native L-Asparaginase
381(3)
B. Sikorska-Fic
K. Makowska
R. Rokicka-Milewska
The Importance of MRI in Detection of Primary CSN Involvement in Leukaemic Children
384(5)
E. Wagiel
K. Wagiel
R. Rokicka-Milewska
All in Adults
Treatment of Adult Acute Lymphoblastic Leukemia Long Term Results of a Prospective Study: LALA 87
389(4)
D. Fiere
J.P. Vernant
M. Michallet
L. Degos
V. Leblond
N. Olteanu
C. Boucheix
C. Charrin
B. Varet
F. Rigal Huguet
A. Delannoy
N. Gratecos
E. Lepage
C. Sebban
Results of Recent Clinical Trials in Acute Lymphoblastic Leukemia by the Cancer and Leukemia Group B
393(9)
R.A. Larson
R.K. Dodge
T.P. Szatrowski
S.R. Frankel
Early Application of Anthracyclines in Adult Acute Lymphoblastic Leukemia (ALL)
402(12)
R. Bassan
A.Z.S. Rohatiner
T. Ledrede
M. Carter
E. DI Bona
E. Pogliani
G. Rossi
P. Fabris
S. Morandi
G. Lamberthengi-Deliliers
P. Casula
M. Vespignani
T.A. Lister
T. Barbui
Allogeneic Bone Marrow Transplantation for BCR-ABL Positive Acute Lymphoblastic Leukemia
414(5)
D.S. Snyder
A.P. Nademanee
M.R. O'Donnell
P.M. Parker
A.S. Stein
K. Margolin
G. Somlo
A. Molina
R. Spielberger
A. Kashyap
H. Fung
N. Vora
M.L. Slovak
J. Niland
J. Palmer
R.S. Negrin
M.D. Amylon
K.G. Blume
S.J. Forman
Preliminary Results of a Risk-Oriented Program for B-Lineage Adult Acute Lymphoblastic Leukemia (ALL): The Collaborative Italian Study 08/96
419(7)
R. Bassan
A. Rambaldi
E. Pogliani
G. Rossi
P. Fabris
S. Morandi
P. Casula
G. Lamberthengi-Deliliers
M. Vespignani
T. Lerede
A. Personeni
P. Bellavita
T. Barbui
Prognostic Factors in Philadelphia+/BCR-ABL+Acute Lymphoblastic Leukemia
426(6)
R. Bassan
A.ZS Rohatiner
E. DI Bona
T. Lerede
M. Carter
A. Rambaldi
E. Pogliani
G. Rossi
P. Fabris
S. Morandi
G. Lamberthengi-Deliliers
T.A. Lister
T. Barbui
High-Dose Cytarabine Combined to Mitoxantrone in the Treatment of Refractory and Relapsed Acute Lymphoblastic Leukemia
432(6)
X. Thomas
N. Bouheddou
D. Fiere
SPLIT-Course High-Dose ARA-C Plus Idarubicin and Multidrug Blockade by short Cyclosporin-A Infusion for Refractory Acute Myeloid Leukemia
438(11)
R. Bassan
T. Lerede
B. Chiodini
A. Rossi
M. Buelli
T. Barbui
AML in Adults
Recent Genetic Studies of Adult Patients with Acute Myeloid Leukemia Performed by the Cancer and Leukemia Group B
449(8)
J.C. Byrd
A.J. Carroll
M.A. Caligiuri
R.A. Larson
C. Bloomfield
The Impact of Treatment on the Outcome of Cytogenetic Subgroups in Acute Myeloid Leukemia - Results of the German AML Cooperative Group
457(4)
W. Hiddemann
T. Buchner
High Dose Cytosine Arabinoside Combined with an Anthracycline as Remission Induction in Acute Myeloid Leukemia
461(3)
S. Fekete
S. Lueff
Comparison of the Efficacy of TAD-TAD and, ,,7+3`` Regimens in Adult AML, the Role of Dose Intensity and Mdr-1 Gene Expression
464(6)
A. Zaritskey
N. Anikina
N. Medvedeva
O. Marinets
Yu. Ogorodnikova
T. Bykova
O. Frolova
L. Peskina
A. Klimovitch
T. Zabelina
L. Zoubarovskaya
E. Kuchinskaya
B. Afanasiev
Stratification of Postremission Therapy in Patients with Acute Myeloid Leukemia ≤ 60 Years According to the Karyotype: Results of the German Multicenter Treatment Trials AML HD93 and AML HD98-A
470(7)
R.F. Schlenk
S. Frohling
F. Del Valle
F. Hartmann
A. Glasmacher
J. Th. Fischer
W. Grimminger
C. Weber
W. Weber U. Gunzer
K. Gotze
C. Waterhouse
A. Benner
K. Dohner
R. Haas
A.D. Ho
H. Dohner
Phase I Trial of Docetaxel (Taxotere) for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
477(5)
T. Szatrowski
M. Hensley
S. Ely
Including Quality of Life as an Important End Point in Evaluating Intensive and Prolonged Treatment for Acute Myeloid Leukemia (AML)
482(6)
A. Schumacher
D. Wewers
T. Buchner
W.E. Berdel
The 10.000/μl Morning Trigger for Prophylactic Platelet Transfusion is Safe: Prospective Experience in 411 AML Patients
488(5)
H. Wandt
M. Frank
Th. Denzel
W. Aulitzky
H. Bodenstein
N. Brack
H. Duerk
R. Engberding
A. Fauser
Th. Geer
B. Germann
M. Gramatzki
J. Kaesberger
J. Kisro
O. Knigge
G. Kochling
R. Kuse
H. Link
A. Neubauer
S. Ohl
P. Pfluger
J. Saal
U. Schakel
K. Schalk
H. Schmidt
S. Soucek
T. Wagner
K. Wilms
G. Ehninger
AML in Children
Prognostic Factors and Patterns of Failure in Childhood Acute Myeloid Leukemia: Experience on Pediatric Oncology Group Study # 8821
493(6)
Y. Ravindranath
M. Chang
S. Raimondi
A.J. Carroll
C.P. Steuber
B. Camitta
H. Weinstein
Early Response to Therapy is the Strongest Prognostic Factor in Childhood AML
499(9)
S.O. Lie
N. Clausen
G. Jonmundsson
L. Mellander
M.A. Siimes
G. Gustafsson
Long-Term Outcome and Prognostic Factors in Children's Cancer Group Study 2891 for Children and Adolescents with Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome
508(11)
B.J. Lange
F.O. Smith
N. Kobrinsky
J. Buckley
W. Howells
J.-W. Lee
J.E. Sanders
St. Neudorf
S. Gold
D. Barnard
J. DeSwarte
K. Dusenbery
D.C. Arthur
W.G. Woods
Risk-Adapted Therapy and Randomization in Children with AML: Preliminary Results of Study AML-BFM 93
519(6)
U. Creutzig
J. Ritter
M. Zimmermann
J. Hermann
H. Gadner
Acute Myeloid Leukemia (AML) in Children: Results of the French Trials
525(6)
G. Schaison
A. Auvrignon
G. Michel
T. Leblanc
A. Baruchel
J.P. Vannier
E. Le Gall
B. Nelken
J.L. Stephan
F. Mechinaud
G. Couillault
G. Leverger
AML in Children: The Medical Research Council Data
531(10)
R.F. Stevens
I.M. Hann
K. Wheatley
R.G. Gray
Preliminary Results of a Multicentre Therapy Study for the Treatment of Children and Adolescents with AML in the Ukraine
541(3)
O. Ryzhak
S. Donska
I. Korenkova
E. Karamanesth
R. Polyschuk
V. Usatchenko
IDA-FLAG - An Effective Reinduction Therapy for Poor Prognosis AML of Childhood - Report of a Multicenter Phase II Trial
544(13)
G. Fleischhack
C. Hassan
N. Graf
G. Mann
U. Bode
Acute Promyelocytic Leukemia
APL Biology
557(5)
B. Cassinat
S. Chevret
N. Balitrand
F. Zassowski
C. Barbey
L. Degos
P. Fenaux
C. Chomienne
Molecular Diagnosis and Monitoring of Acute Promyelocytic Leukemia: Updated Results of the Italian Gimema Group
562(3)
F. LO Coco
D. Diverio
S. De Santis
G. Avvisati
G. Saglio
A. Biondi
F. Mandelli
All-Trans-Retinoic Acid Maintenance for Acute Promyelocytic Leukemia
565(5)
M.S. Tallman
J.W. Andersen
Ch. A. Schiffer
F.R. Appelbaum
J.H. Feusner
A. Ogden
L. Shepherd
Ch. Willman
C.D. Bloomfield
J.M. Rowe
P.H. Wiernik
Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
570(8)
J. Hu
H.-P. Sun
Ch. Niu
H. Yan
T. Yu
G.-Q. Chen
Z.-X. Shen
S.-J. Chen
Z.-Y. Wang
Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refractory and Relapsed Acute Myeloid Leukemia
578(10)
W. Kern
A. Matylis
T. Gruneisen
C. Huber
A. Grote-Metke
B. Wormann
T. Buchner
J. Ohnesorge
W.-D. Ludwig
W. Hiddemann
Acute Promyelocytic Leukemia and Pregnancy
588(4)
A.A.N. Giagounidis
A.S. Giagounidis
M. Beckmann
M. Aivado
T. Emde
A. Heyll
C. Aul
Severe Laryngeal Edema in Acute Promyelocytic Leukemia under All-Trans Retinoic Acid
592(4)
M. Aivado
A.A.N. Giagounidis
A. Rong
T. Emde
A. Grust
A. Heyll
C. Aul
Extramedullary Acute Promyelocytic Leukemia
596(8)
G. Specchia
E.M. Pogliani
D. Pastore
D. Mininni
V. Rossi
A. Mestice
I. Attolico
V. Liso
Chemotherapy and All-Trans Retinoic Acid in Patients >60 Years with Acute Myeloid Leukemia: First Results of the Multicenter Treatment Trial AML HD98-B
604(7)
S. Frohling
R.F. Schlenk
F. Del Valle
F. Hartmann
A. Glasmacher
J.T. Fischer
W. Grimminger
C. Weber
W. Weber
U. Gunzer
K. Gotze
K. Dohner
R. Haas
A.D. Ho
H. Dohner
AML in Elderly Patients
Treatment of Older Patients with Acute Myeloid Leukemia (AML)
611(10)
T. Buchner
W. Hiddemann
C. Schoch
T. Haferlach
H. Eimermacher
P. Staib
L. Balleisen
H.E. Reis
H.-J. Pielken
A. Reichle
H.J. Schmoll
F. Griesinger
A. Gruneisen
M.-C. Sauerland
A. Heinecke
AML in the Elderly
621(7)
E. Estey
J. Cortes
M. Beran
Ch. A. Koller
M.J. Keating
The EORTC-HOVON Approach to the Older Patient with AML: The Use of GM-CSF
628(3)
B. Lowenberg
Therapy of Older Adults with AML: CALGB Studies
631(8)
R.M. Stone
Treatment of Older Adults with Acute Myelogenous Leukemia: Studies of the Eastern Cooperative Oncology Group (ECOG)
639(5)
M.S. Tallman
P.A. Cassileth
P.H. Wiernik
J.M. Rowe
A Landmark Analysis of Survival by Response Category in Elderly Patients with Acute Myeloblastic Leukemia
644(5)
F. Marmont
B. Allione
E. Audisio
C. Boccomini
M.A. Ciocca Vasino
S. D'Ardia
M. Falda
F. Locatelli
E. Gallo
Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes
649(6)
T. De Witte
S. Suciu
G. Verhoef
B. Labar
E. Archimbaud
C. Aul
D. Selleslag
A. Ferrant
P. Wijermans
F. Mandelli
S. Amadori
U. Jehn
P. Muus
H. Demuynck
M. Dardenne
R. Zittoun
R. Willemze
A. Gratwohl
J. Apperley
Secondary Leukemia or Myelodysplasia Treated by Bone Marrow Transplantation
655(5)
R.P. Witherspoon
H.J. Deeg
R. Storb
F.R. Appelbaum
F. Hutchinson
Comparison of Intensive Chemotherapy and Autologous Transplantation as Post Remission Therapy in Adult Acute Myeloid Leukemia, Update of the GOELAM 1 Trial
660(5)
J.L. Harousseau
B. Pignon
M.P. Chevalier
J.Y. Cahn
Adoptive Immunotherapy of Acute Leukemia and Acute Phase Chronic Myeloid Leukemia after Allogeneic Bone Marrow Transplantation
665(9)
C. Schmid
A. Muth
M. Humann
G. Ledderose
C. Salat
R. Munker
M. Schleuning
E. Holler
J.H. Kolb
Shifting Towards Better Immunotherapy Rather Than More Intensive Chemoradiotherapy Using a Non-Myeloablative Approach in Patients with Leukemia
674(4)
S. Slavin
A. Nagler
S. Panigrahi
G. Varadi
A. Ackerstein
S. Samuel
R. Or
Long-Term Results of Autologous Bone Marrow Transplantation as Late Intensification in AML
678(5)
C. Annalaro
G. Lambertenghi-Deliliers
E. Pozzoli
V.G. Bertolli
S. Saviano
A. Della Volpe
D. Soligo
Results of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk MDS
683(2)
C. Aul
U. Germing
A. Niederste-Hollenberg
G. Meckenstock
A. Heyll
Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients
685(10)
M. Bornhauser
C. Thiede
F. Kroschinsky
A. Neubauer
G. Ehninger
Analysis of Chimerism in the Early Posttransplantation Period in Cellular Subsets of Patients Undergoing Myeloablative and Non-Myeloablative (Metakine) Allogeneic Blood Stem Cell Transplantation (BSCT)
695(3)
C. Brendel
C. Thiede
B. Mohr
M. Florek
U. Oelschlagel
M. Ritter
R. Naumann
G. Geissler
G. Ehninger
M. Bornhauser
A. Neubauer
Somnolence Syndrome after Total Body Irradiation in Children with Bone Marrow Transplantation
698(8)
U. Zimmermann
J. Hermann
D. Fuchs
F. Zintl
Ten Years of Autologous Stem Cell Transplantation in Acute Leukemia: Single Center Experience in 46 Patients
706(5)
U. Kaiser
M. Hinz
B. Reckzeh
C. Faoro
G. Zugmaier
M. Wolf
Transplant Characteristics: Minimal Residual Disease and Impaired Megakaryocytic Colony Growth as Sensitive Parameters for Predicting Relapse in Acute Myeloid Leukemia
711(10)
A. Reichle
G. Rothe
S. Krause
M. Zaiss
H. Ullrich
R. Andreesen
Subject Index 721

Supplemental Materials

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

Rewards Program